<DOC>
	<DOCNO>NCT01563432</DOCNO>
	<brief_summary>This study design compare evaluate pharmacokinetic characteristic febuxostat single oral administration TMX-67 ( test drug ) Feburic® tablet healthy adult ; evaluate safety tolerance follow single-dose administration .</brief_summary>
	<brief_title>Clinical Study Evaluate Pharmacokinetic Characteristics Between TMX-67 Feburic® Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Healthy adult male age 20 45 year Subjects whose weight 50 kg BMI 18 29 kg/m2 Subjects voluntarily decide participate study provide write informed consent observe direction Medical history may influence adsorption , distribution , metabolism , excretion drug Clinically significant active chronic disease ( ) Persons deem ineligible study investigator accord clinical laboratory test result reason</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>crossover</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>hyperuricemia</keyword>
	<keyword>gout</keyword>
</DOC>